Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Culley Carson

Urology Chapel Hill, NC Medical Doctor

NPI 1417041633 CMS profile 109473

101 Manning Dr, Chapel Hill, NC 27599

Open in the dashboard

General payments

$274,870

270 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Culley Carson of Chapel Hill, NC is reported in the CMS Open Payments database as having received $274,870 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,180 13
2024 General $10,606 14
2023 General $31,561 35
2022 General $27,106 37
2021 General $33,420 25
2020 General $70,399 63
2019 General $88,597 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Culley Carson
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Culley Carson were reported at $13,180. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Culley Carson Urology median Middle half National median
2019 $88,597 $480 $147–$1,201 $163
2020 $70,399 $246 $87–$645 $114
2021 $33,420 $358 $111–$1,000 $132
2022 $27,106 $476 $143–$1,263 $149
2023 $31,561 $560 $168–$1,461 $160
2024 $10,606 $563 $170–$1,464 $164
2025 $13,180 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $140,641 140 payments
  2. Boston Scientific Corporation $87,610 65 payments
  3. Clarus Therapeutics Inc. $28,546 43 payments
  4. Endo USA, Inc. $17,188 15 payments
  5. Coloplast Corp $689 4 payments
  6. Antares Pharma, Inc. $196 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $181,240 55 payments
  2. Travel and Lodging $33,736 108 payments
  3. Consulting Fee $29,325 8 payments
  4. Honoraria $23,050 10 payments
  5. Food and Beverage $7,519 89 payments
Products named General payments · program years 2019–2025
  1. XIAFLEX $157,828 155 payments
  2. JATENZO testosterone replacement therapy $28,546 43 payments
  3. JATENZO testosterone replacement therapy $28,546 43 payments
  4. JATENZO testosterone replacement therapy $28,546 43 payments
  5. AMS $27,913 17 payments
  6. ADVANCE $16,273 3 payments
  7. GENERAL THERAPIES General Therapies $14,879 20 payments
  8. General Therapies Therapies $8,305 3 payments
  9. General - Erectile Dysfunction $5,750 6 payments
  10. GENERAL ERECTILE DYSFUNCTION $5,000 2 payments
  11. Other $7,782 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record